Cutaneous Larva Migrans Treatment Guidelines

Introduction to Treatment Options

The Centers for Disease Control and Prevention recommends albendazole 400 mg orally daily for 3 days as a treatment option for cutaneous larva migrans, with cure rates ranging from 46-100% 1
The World Health Organization and other authorities support the use of ivermectin and albendazole for the treatment of cutaneous larva migrans, with ivermectin being the preferred option for multiple or diffuse lesions 1, 2

Cutaneous larva migrans is characterized by a serpiginous, itchy rash migrating at 1-2 cm per day, often associated with beach exposure, and typically affects feet, buttocks, and abdomen 1

For standard cases, the World Health Organization suggests ivermectin 200 μg/kg single dose, but if ivermectin is unavailable, albendazole 400 mg daily for 3 days can be considered, with a standard 3-day course recommended to reduce the risk of relapse 1
Ivermectin is recommended at 200 μg/kg as a single oral dose (approximately 12 mg for a 59 kg adult) 1, 2
Albendazole can be used as an alternative, with a dosage of 400 mg orally daily for 3 days 2, 1

In pregnancy, ivermectin should be avoided and albendazole should be used with caution 1, 2
In children, dosing should be adjusted by weight 1, 2
For patients with normal immunity, single dose treatment with ivermectin is typically sufficient 1
For immunocompromised patients, extended treatment may be necessary 1

A study found that albendazole 400 mg orally daily for 3 days is effective in treating cutaneous larva migrans, with cure rates ranging from 46-100%, and a 3-day course is recommended to reduce the risk of relapse 1
Ivermectin is preferred for multiple or diffuse lesions, and is well-tolerated with minimal side effects 1, 2